Chu, Qian

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer

Cancer Immunotherapy and BiomarkersAngiogenesis and VEGF in Cancer

Cited by 608

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology

interferon and immune responsesCancer Immunotherapy and Biomarkers

Cited by 413

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 179

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., et al. (2025) · The Lancet

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 173

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 163

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor

Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 153

Prospects for combining immune checkpoint blockade with PARP inhibition

Li, A., Yi, M., Qin, S., Chu, Q., Luo, S., & Wu, K. (2019) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersPARP inhibition in cancer therapy

Cited by 143

Advances and perspectives of PARP inhibitors

Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 117

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 96

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 69

Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients

Duan, Y.-Q., Xia, M.-H., Ren, L., Zhang, Y.-F., Ao, Q.-L., Xu, S.-P., Kuang, D., Liu, Q., Yan, B., Zhou, Y.-W., et al. (2020) · Current Medical Science

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 59

The role of gut microbiota in immune checkpoint inhibitor therapy

Yi, M., Qin, S., Chu, Q., & Wu, K. (2018) · HepatoBiliary Surgery and Nutrition

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 32

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 14

The biology of combination immunotherapy in recurrent metastatic head and neck cancer

Yuan, X., Yi, M., Zhang, W., Xu, L., Chu, Q., Luo, S., & Wu, K. (2021) · The International Journal of Biochemistry & Cell Biology

Cancer Immunotherapy and BiomarkersHead and Neck Cancer Studies

Cited by 13